A new antibiotic based on drugs developed by AstraZeneca can kill off dangerous bacteria that cause sepsis and pneumonia without harming healthy gut microbes, research in mice shows. If further developed, drugs like it eventually could overcome a major downside to some antibiotics that is linked to serious complications.

We can now envision the oasis that Ionis Pharmaceuticals saw with its hereditary angioedema data.

Ultragenyx is gearing up to take its glycogen storage disease (GSD) treatment to regulators next year after the gene therapy helped patients reduce their intake of cornstarch, which is currently used to treat the disease, in a phase 3 trial.

Baxter put forward clinical data showing that its expanded hemodialysis approach, which aims to filter out a greater range of harmful molecules from the bloodstream, was able to help reduce the number of deaths in a study by a quarter.

Johnson & Johnson’s oral add-on drug significantly improved depressive symptoms and sleep outcomes in a phase 3 trial for patients who previously did not benefit from antidepressants alone.

To speed up drug applications, the FDA has laid out new guidance on how to request a platform designation that can smooth subsequent applications for biotechs working off the same reproducible technology.

AstraZeneca’s small molecule lowered levels of “bad” cholesterol by more than half in patients who had never received treatment for their condition, according to results from an early-stage trial.

Pulsed field ablation has been making waves in cardiac procedures in the past few months following a series of green lights among major devicemakers looking to offer treatments for atrial fibrillation and irregular heart rhythms with fewer side effects. Now, Galvanize Therapeutics is jumping in with its system that broadens the use of the tech to patients with cancer.

The FDA delivered a green light to its first closed-loop, insulin pump-controlling smartphone app that can cover pregnant women with Type 1 diabetes.

After proving the efficacy of a pertussis vaccine in preventing infection, ILiAD Biotechnologies’ next challenge was to add the shot to a Trojan horse lineup of childhood vaccines to see whether they can be co-administered.